
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
This trial found out more about chemotherapy to treat non small cell lung cancer. The trial was open to people with non small cell lung cancer (NSCLC) that had spread. This trial was supported by Cancer Research UK.
Chemotherapy is sometimes used to treat people who have non small cell lung cancer (NSCLC). If you have chemotherapy for NSCLC, you may have cisplatin or carboplatin.
Many doctors use a particular dose of cisplatin. Research suggested that higher doses of this drug may be better at shrinking and controlling the cancer. One of the aims of this trial was to find out the best dose to use.
This trial also compared cisplatin with carboplatin, to see which worked best. Everyone in the trial also had another chemotherapy drug called gemcitabine. Trials have shown that gemcitabine combined with standard drugs can improve lung cancer treatment. So if you took part in this trial you either had
The researchers also wanted to find out how these different treatments affected .
The trial team found that gemcitabine with carboplatin worked just as well as gemcitabine with the highest dose of cisplatin to treat advanced non small cell lung cancer (NSCLC).
This was a randomised trial . It recruited 1,363 people. They were put into 1 of 3 treatment groups and neither they nor their doctor could choose which group they were in.
After an average follow up of 60 months the trial team looked at how many people’s lung cancer had responded to treatment. They found that
The team then looked at the average length of time people lived after treatment. They found it was
The trial team concluded that the combination of gemcitabine and carboplatin worked just as well as the combination of gemcitabine and high dose cisplatin for people with advanced non small cell lung cancer.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists () but may not have been published in a medical journal. The figures we quote above were provided by the research team. We have not analysed the data ourselves.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David R Ferry
Cancer Research UK
Eli Lilly
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/04/009.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”